![]() |
市場調查報告書
商品編碼
1510612
歐洲生物生產市場預測至 2030 年 - 區域分析 - 按產品、應用、設備和最終用戶Europe Bioproduction Market Forecast to 2030 - Regional Analysis - by Product, Application, Equipment, and End User |
2022年歐洲生物生產市場價值為55.1506億美元,預計到2030年將達到147.898億美元;預計2022年至2030年複合年成長率為13.1%。
慢性病盛行率不斷上升推動歐洲生物生產市場
心血管疾病(CVD)、神經系統疾病、自體免疫疾病和癌症是全球造成死亡和殘疾率很高的慢性疾病。根據世界衛生組織 (WHO) 的數據,CVD 是全球第一大死因,估計每年奪去 1,790 萬人的生命。癌症也是全世界死亡的主要原因之一,影響著大量人口。因此,它給社會帶來了巨大的經濟負擔。據世界衛生組織稱,2020 年,全球約有 1,000 萬人死於癌症。然而,越來越多的關於開發有效治療疾病的研究正在積極影響市場的成長。基因療法和細胞療法正在改變癌症治療格局;例如,諾華公司的Kymriah用於治療瀰漫性大B細胞淋巴瘤。
此外,患者、專家、初級保健臨床醫生和其他醫療保健專業人員認知到生物相似藥是有效且安全的藥物,正在推動對生物相似藥的需求。此外,生物相似藥有助於改善數百萬患者的生活,同時每年為醫療保健系統節省數十億美元。它們是治療許多疾病的有效且具成本效益的選擇,包括慢性皮膚病和腸道疾病,如克隆氏症、牛皮癬、腸躁症和結腸炎;糖尿病;自體免疫疾病;癌症;腎臟狀況;和關節炎。
隨著慢性病盛行率的快速成長,用於治療危及生命的疾病的生物生產的需求在過去五年中迅速成長,從而推動了生物生產市場的發展。
歐洲生物生產市場概況
歐洲生物生產市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。歐洲在全球生物生產市場中佔據重要地位,預計 2022-2030 年複合年成長率顯著。慢性病盛行率的不斷上升導致產品上市和批准數量不斷增加,技術進步和投資也不斷增加,從而促進了該地區的市場成長。
生物相似藥引入了競爭並提高了生物製劑的可負擔性,最終提供節省成本和增值服務來支持患者護理和醫療保健行業。醫療保健專業人員可以以更低的成本使用高品質的生物製劑治療更多患者。由於節省成本的巨大潛力,德國衛生部推出了一項新法律來增加生物相似藥的採用。由於一些歐盟 (EU) 國家允許藥劑師取代生物相似藥,這將代表實踐中的重大變化,特別是對德國而言。此外,醫療保健提供者如德國法蘭克福的 PHI 骨科物理治療中心、德國國際診所; CBC Health 慕尼黑,德國;和其他提供者為各種慢性疾病提供幹細胞療法,如糖尿病視網膜病變、視神經神經炎和類風濕性關節炎。預計這將在未來幾年增加細胞療法的採用。此外,國際參與者之間越來越多的合作夥伴關係也促進了市場的成長。例如,2020 年 11 月,Hitachi Chemical Advanced Therapeutics Solutions, LLC 和 apceth Biopharma GmbH 擴大了與 Bluebird Bio 的關係,為多種療法的臨床和商業供應提供長期開發和製造服務協議,包括擴大在歐洲ZYNTEGLO 是一種治療輸血依賴性B 地中海型貧血(TDT) 的一次性基因療法。因此,隨著德國政府擴大採用生物相似藥,該市場預計將蓬勃發展。
歐洲生物生產市場收入及 2030 年預測(百萬美元)
歐洲生物生產市場細分
歐洲生物生產市場分為產品、應用、設備、最終用戶和國家。
根據產品,歐洲生物生產市場分為生物製劑和生物相似藥、疫苗、細胞和基因療法、核酸療法等。到 2022 年,生物製劑和生物相似藥領域將佔據歐洲最大的生物生產市場。
在應用方面,歐洲生物生產市場分為類風濕性關節炎、血液疾病、癌症、糖尿病、心血管疾病等。到 2022 年,癌症領域將佔據歐洲最大的生物生產市場。
依設備分類,歐洲生物生產市場分為上游設備、下游設備、生物反應器、耗材及配件。到 2022 年,消耗品和配件領域將佔據歐洲最大的生物生產市場。
就最終用戶而言,歐洲生物生產市場分為生物製藥公司、合約製造組織等。到 2022 年,生物製藥公司領域將佔據歐洲最大的生物生產市場。
依國家/地區分類,歐洲生物生產市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。 2022 年,德國在歐洲生物生產市場佔有率中佔據主導地位。
Lonza Group AG、bbi-biotech GmbH、Danaher Corp、Sartorius AG、FUJIFILM Irvine Scientific Inc、Thermo Fisher Scientific Inc、Merck KGaA、F. Hoffmann-La Roche Ltd 和 Bio-Rad Laboratories Inc. 是營運中的一些領先公司在歐洲生物生產市場。
表中的內容
The Europe bioproduction market was valued at US$ 5,515.06 million in 2022 and is expected to reach US$ 14,789.80 million by 2030; it is estimated to register a CAGR of 13.1% from 2022 to 2030.
Increasing Prevalence of Chronic Diseases Drives Europe Bioproduction Market
Cardiovascular diseases (CVDs), neurological disorders, autoimmune disorders, and cancer are among the chronic diseases causing death and disabilities at a significant rate worldwide. As per the World Health Organization (WHO), CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Cancer is also among the leading causes of mortality worldwide, affecting a huge population; therefore, it acts as a huge financial burden on society. According to the WHO, in 2020, ~10 million deaths occurred due to cancer globally. However, growing research on developing effective treatments for the disease is positively affecting the market growth. Gene therapy and cell therapy are transforming the cancer treatment landscape; for example, Novartis' Kymriah is used to treat diffuse large B-cell lymphoma.
Moreover, recognition of biosimilars as efficacious and safe agents by patients, specialists, primary care clinicians, and other healthcare professionals is propelling the demand for biosimilars. In addition, biosimilars help improve life of millions of patients while saving billions of dollars of the healthcare system per year. They are effective and cost-effective options in treating many diseases, including chronic skin conditions and bowel diseases such as Crohn's disease, psoriasis, irritable bowel syndrome, and colitis; diabetes; autoimmune disease; cancer; kidney conditions; and arthritis.
As the prevalence of chronic diseases is increasing at a high rate, the demand for bioproduction in treating life-threatening illnesses has progressed rapidly over the last five years, thereby driving the bioproduction market.
Europe Bioproduction Market Overview
The Europe bioproduction market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global bioproduction market and is estimated to register a notable CAGR during 2022-2030. The increasing prevalence of chronic disorders has resulted in a growing number of product launches and approvals, along with technological advancements and investment, thereby contributing to the market growth in the region.
Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare industry. Healthcare professionals can treat more patients with high-quality biologics at reduced cost. Due to the massive potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As a few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. In addition, healthcare providers such as PHI Orthopedic Physiotherapy Center, German International Clinic, Frankfurt, Germany; CBC Health Munich, Germany; and other providers offer stem cell therapy for various chronic diseases such as diabetic retinopathy, optic nerve neuritis, and rheumatoid arthritis. This is expected to increase the adoption of cell therapies in the coming years. Also, a growing number of partnerships among international players boost the market growth. For instance, in November 2020, Hitachi Chemical Advanced Therapeutics Solutions, LLC and apceth Biopharma GmbH expanded their relationship with bluebird bio with long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies, including expanded commercial drug product manufacturing capacity in Europe for ZYNTEGLO, a one-time gene therapy for transfusion-dependent B-thalassemia (TDT). Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to flourish.
Europe Bioproduction Market Revenue and Forecast to 2030 (US$ Million)
Europe Bioproduction Market Segmentation
The Europe bioproduction market is categorized into product, application, equipment, end user, and country.
Based on product, the Europe bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held the largest Europe bioproduction market share in 2022.
In terms of application, the Europe bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held the largest Europe bioproduction market share in 2022.
By equipment, the Europe bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held the largest Europe bioproduction market share in 2022.
In terms of end user, the Europe bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held the largest Europe bioproduction market share in 2022.
By country, the Europe bioproduction market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe bioproduction market share in 2022.
Lonza Group AG, bbi-biotech GmbH, Danaher Corp, Sartorius AG, FUJIFILM Irvine Scientific Inc, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc. are some of the leading companies operating in the Europe bioproduction market.
Table of Content